Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

Pfizer's decision could stem from the fairly dismal performance of the only gene therapy for haemophilia A currently on the ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

Those key challenges impacting the care of respiratory diseases include delays in diagnosis due to the intermittent nature of ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Four years after buying exclusive US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal. Deprexis is an online cognitive ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Looking ahead, the momentum gained in 2024 must be maintained and amplified. By fostering a culture of belonging in the ...

My conclusion, having worked in various regions and corporate settings: don’t be loud. Be yourself. Be decent. Be ...